Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Germany (DAX) (EWG) vs Viatris Inc (VTRS) Price & Performance

iShares MSCI Germany (DAX)Trade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Germany (DAX) vs Viatris Inc — how do they compare? iShares MSCI Germany (DAX) trades at $43.83, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals.

EWGVTRS
Sector
Broad Market / FactorHealth
52-Week High
$44.56$17.86
52-Week Low
$38.08$9.49
Market Cap
$18.69B
Enterprise Value
$30.80B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Germany (DAX)

EWG trades at $43.87 with no recent price change. Technical indicators show a bullish trend from moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. Recent news highlights European Central Bank policy decisions and German economic reforms influencing market sentiment.

The outlook is cautiously optimistic due to bullish technical signals, but limited fundamental data and overbought RSI levels pose risks. Investors should monitor European economic developments and company-specific financial updates for directional cues amid geopolitical and energy price volatility.

Viatris Inc

Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.

Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Germany (DAX)

EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.

Read more on EWG

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS